NCI B CELL LYMPHOMA VACCINE PHASE II TRIAL UNDER WAY
NCI B CELL LYMPHOMA VACCINE PHASE II TRIAL UNDER WAY with custom-made vaccines procured from each participating patient's tumor, the National Cancer Institute announced May 24. The trial, which began in early April, will accrue 100 patients over the next two years. Larry Kwak, senior investigator in NCI's Biological Response Modifiers Program located in Frederick, Md., is leading the study. No company is participating in the trial but NCI eventually would outlicense the program.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth